PMID- 32374188
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20221207
IS  - 1502-7686 (Electronic)
IS  - 0036-5513 (Linking)
VI  - 80
IP  - 5
DP  - 2020 Sep
TI  - Effects of a highly controlled carbohydrate-reduced high-protein diet on markers 
      of oxidatively generated nucleic acid modifications and inflammation in weight 
      stable participants with type 2 diabetes; a randomized controlled trial.
PG  - 401-407
LID - 10.1080/00365513.2020.1759137 [doi]
AB  - Carbohydrate-restricted diets are increasingly recognized as options for dietary 
      management of type 2 diabetes mellitus (T2DM). We investigated the effects of a 
      carbohydrate-reduced high-protein (CRHP) and a conventional diabetes (CD) diet on 
      oxidative stress and inflammation in weight stable individuals with T2DM. We 
      hypothesized that the CRHP diet would improve markers of oxidatively generated 
      RNA and DNA modifications as well as inflammatory parameters. Thirty participants 
      with T2DM were randomized to 6 weeks of CRHP or CD dietary treatment (30/50 
      energy percentage (E%) carbohydrate, 30/17E% protein, 40/33E% fat), followed by a 
      cross-over to the opposite diet for a subsequent 6-week period. All meals were 
      provided during the study and body weight was controlled. Diurnal urine samples 
      were collected after 4 weeks on each diet and oxidatively generated RNA and DNA 
      modifications were measured as 8-oxo-7,8-dihydroguanosine (8-oxoGuo) and 
      8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), respectively. Fasting 
      concentrations of soluble urokinase plasminogen activator receptor, 
      high-sensitivity C-reactive protein, tumor necrosis factor alpha and 
      interleukin-6 were measured before and after 6 weeks of interventions. Compared 
      with the CD diet, the CRHP diet increased 24-hour urinary excretion of 8-oxoGuo 
      by 9.3% (38.6 +/- 12.6 vs. 35.3 +/- 11.0 nmol/24 h, p = .03), whereas 8-oxodG did not 
      differ between diets (24.0 +/- 9.5 vs. 24.8 +/- 11.1 nmol/24 h, p = .17). Changes in 
      plasma inflammatory parameters did not differ between CRHP and CD diets, all 
      p >/= .2. The clinical implications of increased RNA oxidation following a CRHP 
      diet as well as long-term effects of carbohydrate-restriction on markers of 
      oxidatively generated nucleic acid modifications should be a field of future 
      study.
FAU - Skytte, Mads Juul
AU  - Skytte MJ
AUID- ORCID: 0000-0001-6607-2064
AD  - Department of Endocrinology, Copenhagen University Hospital Bispebjerg, 
      Copenhagen, Denmark.
FAU - Samkani, Amirsalar
AU  - Samkani A
AD  - Department of Endocrinology, Copenhagen University Hospital Bispebjerg, 
      Copenhagen, Denmark.
FAU - Astrup, Arne
AU  - Astrup A
AD  - Department of Nutrition, Exercise and Sports, University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Larsen, Thomas Meinert
AU  - Larsen TM
AD  - Department of Nutrition, Exercise and Sports, University of Copenhagen, 
      Copenhagen, Denmark.
FAU - Frystyk, Jan
AU  - Frystyk J
AD  - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
FAU - Poulsen, Henrik Enghusen
AU  - Poulsen HE
AUID- ORCID: 0000-0003-4242-9924
AD  - Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg, 
      Copenhagen, Denmark.
AD  - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
FAU - Henriksen, Trine
AU  - Henriksen T
AD  - Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg, 
      Copenhagen, Denmark.
FAU - Holst, Jens Juul
AU  - Holst JJ
AUID- ORCID: 0000-0001-6853-3805
AD  - Novo Nordisk Foundation Center for Basic Metabolic Research, and Department of 
      Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
FAU - Andersen, Ove
AU  - Andersen O
AUID- ORCID: 0000-0002-2274-548X
AD  - Clinical Research Centre and the Emergency Department, Copenhagen University 
      Hospital Hvidovre, Hvidovre, Denmark.
FAU - Madsbad, Sten
AU  - Madsbad S
AD  - Department of Endocrinology, Copenhagen University Hospital Hvidovre, Hvidovre, 
      Denmark.
FAU - Haugaard, Steen Bendix
AU  - Haugaard SB
AD  - Department of Endocrinology, Copenhagen University Hospital Bispebjerg, 
      Copenhagen, Denmark.
FAU - Krarup, Thure
AU  - Krarup T
AD  - Department of Endocrinology, Copenhagen University Hospital Bispebjerg, 
      Copenhagen, Denmark.
FAU - Larsen, Emil List
AU  - Larsen EL
AD  - Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg, 
      Copenhagen, Denmark.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200506
PL  - England
TA  - Scand J Clin Lab Invest
JT  - Scandinavian journal of clinical and laboratory investigation
JID - 0404375
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-6)
RN  - 0 (Nucleic Acids)
RN  - 0 (Receptors, Urokinase Plasminogen Activator)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 12133JR80S (Guanosine)
RN  - 3868-31-3 (8-hydroxyguanosine)
RN  - 88847-89-6 (8-Hydroxy-2'-Deoxyguanosine)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - 8-Hydroxy-2'-Deoxyguanosine/*urine
MH  - Aged
MH  - Blood Glucose/metabolism
MH  - Body Mass Index
MH  - Body Weight
MH  - C-Reactive Protein/urine
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/blood/*urine
MH  - Diet, Diabetic/*methods
MH  - Diet, High-Protein Low-Carbohydrate/*adverse effects
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Guanosine/*analogs & derivatives/urine
MH  - Humans
MH  - Inflammation
MH  - Interleukin-6/urine
MH  - Male
MH  - Middle Aged
MH  - Nucleic Acids/*urine
MH  - Oxidation-Reduction
MH  - Oxidative Stress
MH  - Receptors, Urokinase Plasminogen Activator/metabolism
MH  - Tumor Necrosis Factor-alpha/urine
OTO - NOTNLM
OT  - 8-dihydro-2'-deoxyguanosine
OT  - 8-dihydroguanosine; 8-oxo-7
OT  - 8-oxo-7
OT  - Type 2 diabetes mellitus
OT  - diet
OT  - low-grade inflammation
OT  - nutrition therapy
OT  - oxidative stress
OT  - soluble urokinase plasminogen activator receptor
EDAT- 2020/05/07 06:00
MHDA- 2021/07/20 06:00
CRDT- 2020/05/07 06:00
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2020/05/07 06:00 [entrez]
AID - 10.1080/00365513.2020.1759137 [doi]
PST - ppublish
SO  - Scand J Clin Lab Invest. 2020 Sep;80(5):401-407. doi: 
      10.1080/00365513.2020.1759137. Epub 2020 May 6.